Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug...

Full description

Saved in:
Bibliographic Details
Main Authors: Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Shadab Mirza, Kuldeep Sharma, Rajan Verma, Ashish Kumar, Mohtashim Lohani
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Cells
Subjects:
triple-negative breast cancer (TNBC)
antibody–drug conjugates
sacituzumab govitecan
neutropenia
ADC sequencing
resistance
Online Access:https://www.mdpi.com/2073-4409/13/24/2126
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2073-4409/13/24/2126

Similar Items